Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
N. Bruyniks, N. Biglia, S. Palacios & A. O. Mueck. (2017) Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 20:3, pages 195-204.
Read now
Read now
T. Tzur, D. Yohai & A. Y. Weintraub. (2016) The role of local estrogen therapy in the management of pelvic floor disorders. Climacteric 19:2, pages 162-171.
Read now
Read now
R. J. Santen. (2015) Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 18:2, pages 121-134.
Read now
Read now
Sarah H Lindahl. (2014) Reviewing the options for local estrogen treatment of vaginal atrophy. International Journal of Women's Health 6, pages 307-312.
Read now
Read now
J. A. Simon & R. V. Maamari. (2013) Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric 16:sup1, pages 37-43.
Read now
Read now
R. E. Nappi & M. Kokot-Kierepa. (2012) Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 15:1, pages 36-44.
Read now
Read now
Janet A Chollet. (2011) Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Preference and Adherence 5, pages 571-574.
Read now
Read now
L. S. G. Ulrich. (2011) Endometrial cancer, types, prognosis, female hormones and antihormones. Climacteric 14:4, pages 418-425.
Read now
Read now
D. W. Sturdee & A. Pines. (2011) Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14:3, pages 302-320.
Read now
Read now
D. W. Sturdee & N. Panay. (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:6, pages 509-522.
Read now
Read now
Articles from other publishers (27)
Tomáš Fait. (2023) Climacteric patient in office of general practitioner. Medicína pro praxi 20:3, pages 157-162.
Crossref
Crossref
Frank Z. Stanczyk, Rachel S. Mandelbaum, Harpreet Matharu, Christina E. Dancz & Mark E. Sherman. (2023) Endometrial safety of low-dose vaginal estrogens. Menopause 30:6, pages 650-658.
Crossref
Crossref
E. V. Tikhomirova, V. E. Balan & O. S. Fomina-Nilova. (2020) Current treatment options for genitourinary syndrome. Meditsinskiy sovet = Medical Council:13, pages 91-96.
Crossref
Crossref
Manuela Cristina Russu. 2020. Hormone Therapy and Replacement in Cancer and Aging-related Diseases. Hormone Therapy and Replacement in Cancer and Aging-related Diseases.
Carolyn J. Crandall, Allison Diamant & Nanette Santoro. (2020) Safety of vaginal estrogens: a systematic review. Menopause 27:3, pages 339-360.
Crossref
Crossref
Richard J. Santen, Sebastian Mirkin, Brian Bernick & Ginger D. Constantine. (2020) Systemic estradiol levels with low-dose vaginal estrogens. Menopause 27:3, pages 361-370.
Crossref
Crossref
Ginger D. Constantine, Shelli Graham, Kate Lapane, Kathleen Ohleth, Brian Bernick, James Liu & Sebastian Mirkin. (2019) Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause 26:7, pages 800-807.
Crossref
Crossref
Joan Pitkin. (2018) BMS – Consensus statement. Post Reproductive Health 24:3, pages 133-138.
Crossref
Crossref
Cynthia A. Stuenkel. (2018) More evidence why the product labeling for low-dose vaginal estrogen should be changed?. Menopause 25:1, pages 4-6.
Crossref
Crossref
Carolyn J. Crandall, Kathleen M. Hovey, Christopher A. Andrews, Rowan T. Chlebowski, Marcia L. Stefanick, Dorothy S. Lane, Jan Shifren, Chu ChenAndrew M. Kaunitz, Jane A. Cauley & JoAnn E. Manson. (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 25:1, pages 11-20.
Crossref
Crossref
Ginger D. Constantine, James A. Simon, James H. Pickar, David F. Archer, Harvey Kushner, Brian BernickGina GasperShelli GrahamSebastian Mirkin. (2017) The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause 24:4, pages 409-416.
Crossref
Crossref
Fernand Labrie & Céline Martel. (2017) A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Hormone Molecular Biology and Clinical Investigation 29:2, pages 39-60.
Crossref
Crossref
Meena Dayal & Preeti Yadav. (2017) Management of Postmenopausal Vaginal Atrophy: Review of Literature. Journal of SAFOMS 5:1, pages 51-57.
Crossref
Crossref
Supriya Bulchandani, Philip Toozs-Hobson, Tina Verghese & Pallavi Latthe. (2015) Does vaginal estrogen treatment with support pessaries in vaginal prolapse reduce complications?. Post Reproductive Health 21:4, pages 141-145.
Crossref
Crossref
T. Benoit, P. Leguevaque, M. Roumiguié, J.B. Beauval, B. Malavaud, M. Soulié, P. Rischmann, P. Gourdy, J.F. Arnal & X. Game. (2015) Œstrogénothérapie locale en urologie et pelvi-périnéologie. Revue de littérature. Progrès en Urologie 25:11, pages 628-635.
Crossref
Crossref
David F. Archer. (2015) Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. The Journal of Steroid Biochemistry and Molecular Biology 145, pages 139-143.
Crossref
Crossref
David Sturdee. (2014) Urogenital atrophy. Post Reproductive Health 20:2, pages 73-75.
Crossref
Crossref
. (2013) Management of symptomatic vulvovaginal atrophy. Menopause 20:9, pages 888-902.
Crossref
Crossref
Surveen Ghumman. (2013) Atrophic Vaginitis: Diagnosis and Treatment. Journal of SAFOMS 1:1, pages 4-12.
Crossref
Crossref
Savita Singh, Ineke van Herwijnen & Christian Phillips. (2013) The management of lower urogenital changes in the menopause. Menopause International 19:2, pages 77-81.
Crossref
Crossref
Nancy Fugate Woods. (2012) An Overview of Chronic Vaginal Atrophy and Options for Symptom Management. Nursing for Women's Health 16:6, pages 482-494.
Crossref
Crossref
Santiago Palacios, M. Jesús Cancelo, Camil Castelo-Branco, Silvia González & Miguel Ángel Olalla. (2012) Recomendaciones de la Sociedad Española de Ginecología y Obstetricia sobre la prevención y el tratamiento de la atrofia vaginal. Progresos de Obstetricia y Ginecología 55:8, pages 408-415.
Crossref
Crossref
Margaret Rees, Faustino R. Pérez-López, Iuliana Ceasu, Herman Depypere, Tamer Erel, Irene Lambrinoudaki, Karin Schenck-Gustafsson, Tommaso Simoncini, Yvonne T. van der Schouw & Florence Tremollieres. (2012) EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 73:2, pages 171-174.
Crossref
Crossref
Nick Panay & Ricardo Maamari. (2012) Treatment of postmenopausal vaginal atrophy with 10-µg estradiol vaginal tablets. Menopause International 18:1, pages 15-19.
Crossref
Crossref
Nick Panay. 2012. Dewhurst's Textbook of Obstetrics & Gynaecology. Dewhurst's Textbook of Obstetrics & Gynaecology
553
564
.
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:11, pages i-xii.
Crossref
Crossref
James Simon, Lila Nachtigall, Lian G. Ulrich, Michaela Eugster-Hausmann & Robert Gut. (2010) Endometrial Safety of Ultra-Low-Dose Estradiol Vaginal Tablets. Obstetrics & Gynecology 116:4, pages 876-883.
Crossref
Crossref